ScripStock market turmoil due to macroeconomic uncertainty and biopharmaceutical industry-specific concerns have made it more difficult for publicly traded drug developers to pursue follow-on public offeri
ScripSoleno Therapeutics has gained US approval for Vykat XR, making it the first ever drug to treat hyperphagia, an intense, persistent hunger experienced by people with the rare genetic disorder Prader-W
Pink SheetThe European Medicines Agency was this week deciding whether the planned EU marketing authorization applications (MAAs) for three investigational products deserved accelerated assessments – apitegroma
Pink SheetThe disruption of existing markets is a dominant ambition of the nearly 20 applications expecting US Food and Drug Administration action in March. The Pink Sheet ’s US FDA Performance Tracker shows